Pieter Sonneveld
#109,492
Most Influential Person Now
Researcher
Pieter Sonneveld's AcademicInfluence.com Rankings
Pieter Sonneveldcomputer-science Degrees
Computer Science
#4090
World Rank
#4306
Historical Rank
Machine Learning
#702
World Rank
#712
Historical Rank
Artificial Intelligence
#902
World Rank
#919
Historical Rank
Database
#1326
World Rank
#1398
Historical Rank
Download Badge
Computer Science
Pieter Sonneveld's Degrees
- PhD Computer Science Delft University of Technology
- Masters Artificial Intelligence University of Amsterdam
- Bachelors Computer Science University of Amsterdam
Similar Degrees You Can Earn
Why Is Pieter Sonneveld Influential?
(Suggest an Edit or Addition)Pieter Sonneveld's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. (1995) (2257)
- Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
- International uniform response criteria for multiple myeloma (2006) (2014)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (2005) (1965)
- International staging system for multiple myeloma. (2005) (1929)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. (2015) (1274)
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. (2016) (1132)
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
- High-dose daunorubicin in older patients with acute myeloid leukemia. (2009) (754)
- Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. (2012) (740)
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) (718)
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. (2013) (684)
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010) (660)
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. (2016) (582)
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (2019) (520)
- International uniform response criteria for multiple myeloma (2006) (519)
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. (2007) (515)
- Multiple myeloma (2017) (514)
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. (2007) (506)
- IMWG consensus on risk stratification in multiple myeloma (2014) (473)
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders (2008) (446)
- Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. (2003) (445)
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) (423)
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (2012) (409)
- Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. (2003) (394)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (378)
- Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. (2010) (365)
- High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. (2003) (361)
- Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. (2006) (360)
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. (2012) (343)
- Modulation of multidrug-resistant multiple myeloma by cyclosporin (1992) (334)
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). (2011) (328)
- International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. (2014) (318)
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. (2011) (313)
- Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands (2004) (311)
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline (2009) (300)
- Thalidomide for treatment of multiple myeloma: 10 years later. (2008) (296)
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
- Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. (2015) (293)
- Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. (1995) (289)
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group (2013) (289)
- Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. (1995) (285)
- A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. (2010) (285)
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications (2015) (283)
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. (2018) (279)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (279)
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. (2016) (277)
- Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. (2010) (272)
- Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and (1998) (271)
- Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. (2010) (268)
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis (2018) (266)
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. (2011) (261)
- Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (2007) (259)
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. (2011) (258)
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. (2008) (255)
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. (2016) (251)
- Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders (2012) (250)
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. (2014) (239)
- The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. (2009) (235)
- Management of treatment-emergent peripheral neuropathy in multiple myeloma (2012) (229)
- Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. (2013) (228)
- Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. (2009) (220)
- Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. (1990) (219)
- Cytarabine dose for acute myeloid leukemia. (2011) (215)
- Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. (2010) (214)
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG) (2014) (211)
- Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. (2010) (204)
- International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR (2018) (202)
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. (2008) (198)
- Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. (1995) (194)
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. (2019) (191)
- IMWG consensus on maintenance therapy in multiple myeloma. (2012) (191)
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma (2014) (191)
- Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma (2005) (190)
- A gene expression signature for high-risk multiple myeloma (2012) (185)
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials (2013) (181)
- Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study (2008) (180)
- CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. (2003) (176)
- Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) (2002) (176)
- Comparison of modern and conventional imaging techniques in establishing multiple myeloma‐related bone disease: a systematic review (2013) (173)
- Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. (2016) (172)
- Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial. (2011) (172)
- Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project (2013) (172)
- Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). (2013) (172)
- Vaults: a ribonucleoprotein particle involved in drug resistance? (2003) (167)
- Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. (1993) (166)
- Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. (2009) (161)
- A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients (2017) (161)
- Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. (2002) (161)
- Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. (2008) (159)
- Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2021) (156)
- Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma (2008) (156)
- Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. (1998) (155)
- The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. (2005) (151)
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial (2018) (144)
- Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud (2020) (144)
- Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. (2014) (144)
- International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation (2009) (143)
- Survival and years of life lost in different age cohorts of patients with multiple myeloma. (2010) (142)
- Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. (1990) (140)
- A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma (2013) (138)
- Genome-wide association study identifies multiple susceptibility loci for multiple myeloma (2016) (136)
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
- Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. (2010) (133)
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. (2014) (133)
- Overexpression of the MDRL gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin‐A (1990) (129)
- The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. (2000) (128)
- Multidrug resistance in haematological malignancies (2000) (122)
- The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. (2004) (122)
- Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma (2008) (121)
- Treatment of relapsed and refractory multiple myeloma (2016) (121)
- High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. (2013) (120)
- The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network (2014) (120)
- Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. (2008) (118)
- Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells. (2001) (118)
- Safety and efficacy of bortezomib in high‐risk and elderly patients with relapsed multiple myeloma (2007) (114)
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement (2011) (114)
- Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial (2014) (113)
- Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma (2014) (112)
- Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. (1994) (111)
- The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (2008) (111)
- Phase III study of PSC‐833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95) (2006) (111)
- MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia (1997) (108)
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years (2015) (108)
- Health‐related quality of life and disease‐specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population‐based study using the PROFILES registry (2012) (106)
- CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age (2007) (104)
- Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma (1999) (104)
- From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives (2017) (104)
- A practical update on the use of bortezomib in the management of multiple myeloma. (2006) (104)
- Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. (1996) (102)
- Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. (2011) (102)
- Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. (2014) (99)
- Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy (2004) (99)
- Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) (2020) (98)
- The vault complex (2003) (97)
- Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. (2016) (97)
- Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. (2011) (97)
- HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM) (2010) (96)
- A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors (2004) (95)
- Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. (2007) (94)
- Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective (2010) (94)
- Review of health-related quality of life data in multiple myeloma patients treated with novel agents (2013) (94)
- Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. (2012) (93)
- Clinical relevance of P-glycoprotein expression in haematological malignancies. (1994) (93)
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma (2008) (93)
- Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. (2017) (93)
- Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC–HOVON randomized phase III study (06914) (2001) (92)
- European perspective on multiple myeloma treatment strategies in 2014. (2014) (92)
- Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. (1996) (92)
- Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. (2007) (91)
- Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up (2021) (91)
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. (2021) (90)
- Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. (1999) (90)
- MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. (2001) (89)
- Reversal of drug‐resistance by cyclosporin‐A in a patient with acute myelocytic leukaemia (1990) (89)
- Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. (2015) (89)
- Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer. (1990) (88)
- Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. (1994) (88)
- First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) (2008) (87)
- Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. (1998) (86)
- Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. (2003) (86)
- Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors (2014) (84)
- Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. (2012) (83)
- Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. (2002) (82)
- Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) (81)
- European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018) (80)
- The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group (2010) (79)
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
- Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. (2018) (78)
- European perspective on multiple myeloma treatment strategies: update following recent congresses. (2012) (77)
- High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study. (2009) (77)
- MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. (1994) (76)
- Treatment of relapsed and refractory multiple myeloma in the era of novel agents. (2011) (76)
- European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when (2018) (75)
- Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) (2018) (75)
- Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02/HO95 Study (2017) (75)
- Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. (2012) (74)
- Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis. (2020) (73)
- Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials (2013) (73)
- Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. (2007) (73)
- Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat. (1978) (72)
- Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato‐Oncology Co‐operative Group (HOVON) and Swiss Group for Clinical Cancer Research (2005) (72)
- Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. (1997) (72)
- Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. (2008) (71)
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy (2008) (70)
- Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012 (2016) (70)
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network (2020) (70)
- Self‐reported quality of life in elderly patients with aggressive non‐Hodgkin's lymphoma treated with CHOP chemotherapy (2005) (69)
- Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield (2007) (69)
- Expression of the mdr3 gene in prolymphocytic leukemia: Association with cyclosporin‐a‐induced increase in drug accumulation (1990) (69)
- Genetic Variations in the Glucocorticoid Receptor Gene Are Not Related to Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia (2005) (68)
- Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. (2010) (68)
- Drug resistance in multiple myeloma. (1999) (68)
- Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. (2016) (67)
- Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. (2008) (67)
- Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy (2011) (67)
- Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma (2005) (65)
- Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. (1995) (65)
- Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study (2008) (65)
- A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis (2014) (64)
- Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. (2006) (62)
- Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma (2007) (62)
- Multiple Human Vault RNAs (2001) (62)
- Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial (2007) (62)
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial. (2005) (61)
- A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study. (2004) (61)
- Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). (2016) (60)
- Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. (2015) (60)
- High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. (1993) (59)
- Treatment of relapsed and refractory multiple myeloma (2016) (59)
- Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis (2018) (59)
- Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. (1993) (59)
- Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. (1990) (59)
- Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) (2018) (58)
- Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study (2008) (58)
- Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. (2003) (58)
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. (2019) (58)
- High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. (2019) (58)
- Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. (1993) (58)
- MicroRNA signatures characterize multiple myeloma patients (2011) (57)
- Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma (2015) (57)
- BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. (2017) (57)
- Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma. (2010) (57)
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network (2017) (57)
- The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape (2021) (57)
- Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. (2008) (57)
- Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients (2011) (56)
- High expression of the multidrug resistance‐associated protein (MRP) in chronic and prolymphocytic leukaemia (1994) (56)
- Management of multiple myeloma in the relapsed/refractory patient. (2017) (56)
- Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. (2000) (56)
- Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. (2014) (55)
- Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin (2010) (54)
- Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. (1996) (52)
- Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. (2009) (52)
- Structural domains of vault proteins: a role for the coiled coil domain in vault assembly. (2002) (52)
- Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. (2019) (51)
- Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. (2020) (51)
- Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents (2013) (51)
- Chemotherapy resistance in acute myeloid leukaemia. (2001) (50)
- Gene signature combinations improve prognostic stratification of multiple myeloma patients (2016) (49)
- Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. (2020) (49)
- Age and aging in blood disorders: multiple myeloma (2014) (49)
- The myeloma stem cell concept, revisited: from phenomenology to operational terms (2016) (48)
- ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients (2006) (47)
- High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. (1992) (47)
- Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients (2003) (46)
- Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study (2017) (45)
- How to manage neutropenia in multiple myeloma. (2012) (45)
- Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma. (2016) (45)
- Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype (1992) (45)
- Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. (2018) (45)
- Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status 1 (2004) (45)
- Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia. (1988) (44)
- Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. (2006) (44)
- Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia. (2005) (43)
- Analysis of multidrug‐resistance (MDR‐1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma (1993) (43)
- A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma (2017) (43)
- Dealing with neuropathy in plasma-cell dyscrasias. (2010) (43)
- Functional characteristics of photochemically treated platelets (2004) (41)
- Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma (2016) (41)
- Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). (2006) (41)
- Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. (2015) (41)
- RPL5 on 1p22.1 is recurrently deleted in multiple myeloma and its expression is linked to bortezomib response (2016) (41)
- Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. (2009) (41)
- Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) (2016) (40)
- Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults. (2004) (40)
- P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy (2000) (40)
- Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis (2005) (40)
- Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease (2017) (40)
- Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival (2016) (40)
- How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? (2017) (39)
- Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study (2019) (39)
- Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) (2016) (39)
- Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma (2007) (39)
- Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. (2011) (39)
- Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations (2021) (39)
- Chemotherapy-induced peripheral neuropathies in hematological malignancies (2014) (39)
- Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? (1999) (39)
- Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (39)
- A cost‐effectiveness analysis of real‐world treatment for elderly patients with multiple myeloma using a full disease model (2016) (38)
- A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma (2016) (38)
- Bortezomib vs. dexamethasone in relapsed multiple myeloma: A phase 3 randomized study. (2004) (38)
- Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project (2022) (38)
- Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders. (2007) (38)
- Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch (2006) (38)
- Intensive versus double intensive therapy in untreated multiple myeloma (2004) (37)
- Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma (1999) (37)
- Lenalidomide: a new therapy for multiple myeloma. (2008) (37)
- Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial (2015) (37)
- Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues (2007) (37)
- Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients (2018) (37)
- Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension (2019) (37)
- Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284) (2006) (37)
- Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells. (1983) (36)
- Malignant histiocytosis: a reassessment of cases formerly classified as histiocytic neoplasms and review of the literature. (1995) (36)
- Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (2016) (36)
- Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial (2010) (35)
- Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail. (2005) (35)
- Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies (2018) (35)
- Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. (2004) (35)
- The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands. (2015) (35)
- The transferrin/log(ferritin) ratio: a new tool for the diagnosis of iron deficiency anemia (2012) (35)
- Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma (2016) (35)
- A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma (2017) (35)
- Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation (2015) (34)
- Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome. (2011) (34)
- Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma (2019) (34)
- Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. (2021) (34)
- Long persistence of doxorubicin in human skin after extravasation. (1984) (33)
- Inhibitors of multidrug resistance (1997) (33)
- Insights on Multiple Myeloma Treatment Strategies (2018) (33)
- Clinicopathological diagnosis and treatment of malignant histiocytosis (1990) (33)
- First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). (2019) (33)
- Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma (2017) (33)
- Efflux Kinetics and Intracellular Distribution of Daunorubicin Are Not Affected by Major Vault Protein/Lung Resistance-Related Protein (Vault) Expression (2004) (33)
- Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope. (2005) (33)
- Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis. (2002) (33)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma (2016) (32)
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) (32)
- Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial) (2016) (32)
- Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021) (32)
- Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia (2010) (32)
- The formation of vault-tubes: a dynamic interaction between vaults and vault PARP (2003) (32)
- Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis (2018) (31)
- Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON). (1994) (31)
- Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry (2015) (31)
- Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma (2015) (31)
- A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group (1998) (30)
- In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells. (1996) (30)
- Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. (1994) (30)
- International uniform response criteria for multiple myeloma (2007) (30)
- A gene expression signature for high-risk multiple myeloma (2014) (29)
- Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease (2019) (29)
- Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups. (2005) (29)
- Identification of multidrug resistance‐associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine (2004) (29)
- Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. (2005) (29)
- [Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols]. (2005) (29)
- Richter's syndrome with identical immunoglobulin gene rearrangements in the chronic lymphocytic leukemia and the supervening non-Hodgkin lymphoma. (1989) (29)
- Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. (2016) (29)
- Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma (2009) (29)
- Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. (2006) (29)
- Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cell determined by flow cytometry. (1981) (28)
- Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients (pts) with Multiple Myeloma (MM): Four-Year Update of Castor (2019) (28)
- Predictive value of alkaline phosphatase for response and time to progression in bortezomib‐treated multiple myeloma patients (2007) (28)
- Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells. (1989) (28)
- Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate (2012) (28)
- Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study (2018) (28)
- HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody (2005) (28)
- Resistance to chemotherapy in acute leukemia (1998) (28)
- Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. (2005) (27)
- Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma (2015) (27)
- Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial (2019) (27)
- Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. (2021) (27)
- Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML) (2001) (26)
- Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. (2000) (26)
- The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes. (1990) (26)
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma (2022) (26)
- Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs (2019) (26)
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk (2020) (26)
- Screening for gastrointestinal malignancy in patients with iron deficiency anemia by general practitioners: An observational study (2011) (26)
- Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma (2018) (26)
- Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study. (2009) (26)
- In vitro Ig‐synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors (1991) (26)
- The role of superoxide anions in the development of distant tumour recurrence (2006) (26)
- HOVON 50/GMMG-HD3-trial: Phase III study on the effect of thalidomide combined with high dose melphalan in myeloma patients up to 65 years. (2005) (26)
- Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma (2020) (26)
- General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. (2012) (25)
- Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 (2018) (25)
- Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd (2020) (25)
- LEADING ARTICLE International uniform response criteria for multiple myeloma (2006) (25)
- First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (25)
- Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. (1996) (25)
- MP versus MPT for previously untreated elderly patients with multiple myeloma: A meta-analysis of 1,682 individual patient data from six randomized clinical trials. (2010) (25)
- Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). (2019) (25)
- Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. (2008) (25)
- Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology (2018) (25)
- Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib-induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain (2018) (24)
- The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma (2017) (24)
- Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. (2018) (24)
- Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma (2015) (24)
- Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma (2018) (24)
- Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects (2018) (24)
- Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. (2007) (24)
- In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. (1988) (23)
- Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHA-DEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients With Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN (2011) (23)
- Intermediate‐dose melphalan (IDM) combined with G‐CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma (1996) (23)
- Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched study (2014) (23)
- Incidence of cataracts in rhesus monkeys treated with whole-body irradiation. (1979) (23)
- Risk and management of thrombosis in multiple myeloma. (2012) (23)
- Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study. (2004) (23)
- Polymorphonuclear leukocytes increase the adhesion of circulating tumor cells to microvascular endothelium. (2007) (23)
- Bortezomib Induction and Maintenance Treatment Improves Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-65/GMMG-HD4 Trial (2013) (23)
- Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial (2021) (23)
- Significant difference in outcome for adolescents with acute lymphoblastic leukemia (ALL) treated on pediatric versus adult ALL protocols. (2003) (22)
- Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma (2017) (22)
- Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial (2019) (22)
- Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data (2004) (22)
- Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. (2018) (22)
- Unimpaired dendritic cell functions in MVP/LRP knockout mice (2003) (22)
- Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial (2018) (22)
- Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse (2020) (22)
- Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. (2022) (21)
- OCEAN: a randomized Phase III study of melphalan flufenamide + dexamethasone to treat relapsed refractory multiple myeloma. (2020) (21)
- Diagnosis and risk stratification in multiple myeloma. (2014) (21)
- MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7 (2001) (21)
- Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age (2013) (21)
- Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials (2018) (21)
- Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7). (1988) (21)
- European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma (2021) (21)
- Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate (2004) (20)
- Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. (2010) (20)
- Bortezomib appears to overcome poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials (2005) (20)
- Prevalence of potential underlying aetiology of macrocytic anaemia in Dutch general practice (2016) (20)
- Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study (2018) (19)
- Bortezomib-induced polyneuropathy. (2013) (19)
- Reversal of multidrug resistance in hematological malignancies. (1999) (19)
- Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. (2017) (19)
- Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220) (2019) (19)
- Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients. (2006) (19)
- Front-line treatment in younger patients with multiple myeloma. (2009) (19)
- Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM) (2008) (19)
- Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. (2005) (18)
- Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed myeloma (2005) (18)
- Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial. (2017) (18)
- Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients (2018) (18)
- Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology. (2011) (18)
- Hematologic Profiles in the Phase 3 APEX Trial. (2005) (18)
- Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression (2011) (18)
- Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study (2019) (18)
- Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study (2019) (17)
- Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus (2022) (17)
- Enhanced chemosensitivity in acute myeloid leukemia by hematopoietic growth factors: a comparison of the MTT assay with a clonogenic assay. (1993) (17)
- Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA (2019) (17)
- Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. (2020) (17)
- Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future (2021) (17)
- 10 Multidrug resistance in acute myeloid leukaemia (1996) (17)
- Drug resistance in multiple myeloma. (1999) (17)
- Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. (2017) (17)
- Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis (2019) (17)
- Differences in the pharmacokinetics of daunomycin in normal and leukemic rats. (1985) (17)
- Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312) (2004) (17)
- Clinical ef fi cacy and management of monoclonal antibodies targeting CD 38 and SLAMF 7 in multiple myeloma (2016) (17)
- Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies (2012) (16)
- Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. (2015) (16)
- Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network (2019) (16)
- GeneticVariations in the Glucocorticoid Receptor GeneAre Not Related to Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia (2005) (16)
- Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology (2015) (16)
- Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM) (2013) (16)
- Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas (2005) (16)
- Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone (2007) (16)
- Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. (2011) (16)
- Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study. (2012) (16)
- Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. (2021) (16)
- Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study (2019) (16)
- A Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of a novel histone deacetylase inhibitor LAQ824 in patients with hematologic malignancies. (2004) (16)
- European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma (2010) (16)
- Long-term Outcomes in Patients With Multiple Myeloma (2018) (15)
- A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform (2020) (15)
- Bortezomib-Based Induction Therapy Followed by Autologous Stem Cell Transplantation and Maintenance Therapy with Bortezomib Improves Outcome In Myeloma Patients with Gain 1q21 and t(4;14) - a Subgroup Analysis of the HOVON-65/GMMG-HD4 Trial (2010) (15)
- Interleukin‐6 and Interleukin‐1 enhancement of GM‐CSF‐dependent proliferation of haematopoietic progenitor cells in myelodysplastic syndromes (1991) (15)
- Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities (2020) (15)
- The genomic sequence of the murine major vault protein and its promoter. (2002) (15)
- Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. (1996) (14)
- Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma (2021) (14)
- RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. (2018) (14)
- Search for multiple myeloma risk factors using Mendelian randomization. (2020) (14)
- Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment (1998) (14)
- Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial. (2018) (14)
- The expression of the Peripheral Cannabinoid receptor on cells of the immune system and Non-Hodgkin's lymphomas (2007) (14)
- Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethason In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network (2013) (14)
- Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study (2020) (13)
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. (2020) (13)
- Intensive versus double intensive therapy in untreated multiple myeloma : Final analysis of the HOVON 24 trial. (2005) (13)
- Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients. (2009) (13)
- Global Myeloma Research Clusters, Output, and Citations: A Bibliometric Mapping and Clustering Analysis (2015) (13)
- Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value (2012) (13)
- Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma (2021) (13)
- Oprozomib in patients with newly diagnosed multiple myeloma (2019) (13)
- Increased uptake and accumulation of cobalamin by multiple myeloma bone marrow cells as a possible cause of low serum cobalamin (1993) (13)
- Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients (2016) (13)
- Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts (1997) (13)
- Efficacy of Daratumumab in Combination with Standard of Care Regimens in Lenalidomide-Exposed or -Refractory Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of the Castor, Pollux, and MMY1001 Studies (2018) (13)
- Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment. (2003) (13)
- Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma (2021) (13)
- Different distribution of adriamycin in normal and leukaemic rats. (1981) (12)
- Cost analysis of CHOP (‐like) chemotherapy regimens for patients with newly diagnosed aggressive non‐Hodgkin's lymphoma (2002) (12)
- Manipulation of cell cycle kinetics: Influence on the cytotoxicity of doxorubicin in human breast cancer cells (1990) (12)
- Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial. (2016) (12)
- Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes (2019) (12)
- Economic assessment in the management of non-Hodgkin’s lymphoma (2004) (12)
- Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function (2017) (12)
- A016 Donor Versus No-Donor Analysis of Newly Diagnosed Myeloma Patients included in the HOVON-50/54 Study (2009) (12)
- Immunophenotyping as a guide for targeted therapy. (2003) (12)
- Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival (2015) (11)
- Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study (2021) (11)
- Six courses of intensified CHOP plus G-CSF compared to eight courses of standard CHOP in patients with intermediate-risk aggressive non-Hodgkin lymphoma (2005) (11)
- Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1 (2021) (11)
- Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment (2009) (11)
- The effect of whole-body irradiation on skeletal growth in rhesus monkeys. (1979) (11)
- Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients (2011) (11)
- 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde (2021) (11)
- Expression of mdr1 and mdr3 multidrug-resistance genes in hairy cell leukaemia. (1991) (11)
- Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors (2014) (11)
- Secondary malignancies in elderly myeloma patients (2011) (11)
- Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial. (2019) (11)
- A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma (2013) (11)
- First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network (2020) (10)
- Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? (2012) (10)
- The combined effects of Il-3, GM-CSF and G-CSF on the in vitro growth of myelodysplastic myeloid progenitor cells. (1990) (10)
- A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma, (2011) (10)
- Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response (2021) (10)
- 18F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma (2016) (10)
- CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy (2021) (10)
- Cytokine and viral load kinetics in human herpesvirus 8-associated multicentric Castleman’s disease complicated by hemophagocytic lymphohistiocytosis (2016) (10)
- Perspectives on the Risk-Stratified Treatment of Multiple Myeloma (2022) (10)
- A phase II multicenter study of CNTO 328, an anti-IL-6 monoclonal antibody, in patients (pts) with relapsed or refractory multiple myeloma (MM). (2009) (10)
- Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO). (2018) (10)
- Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma (1990) (10)
- A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma. (2003) (9)
- High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group (2013) (9)
- Daratumumab and Blood-Compatibility Testing. (2016) (9)
- Donor Versus No Donor Analysis of Newly Diagnosed Myeloma Patients Included in the HOVON 50/54 Study (2008) (9)
- A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients (2016) (9)
- [Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma]. (1999) (9)
- Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? (2014) (9)
- Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study (2018) (9)
- Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion (2004) (9)
- The prognostic significance of chromosomal findings in patients with acute myeloid leukemia in a study comparing the efficacy of autologous and allogeneic bone marrow transplantation. (1991) (9)
- Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma. (2000) (9)
- Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis (2019) (9)
- Gain of 1q21 in multiple myeloma: from bad to worse? (2006) (9)
- Clinical modulation of multidrug resistance in VAD-refractory multiple myeloma: studies with cyclosporin and SDZ PSC 833 (1994) (9)
- Phase 1 / 2 study to assess the safety , efficacy , and pharmacokinetics of barasertib ( AZD 1152 ) in patients with advanced acute myeloid leukemia (2011) (9)
- Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. (2017) (9)
- Treatment with Arsenic Trioxide, Ascorbic Acid and Dexamethasone in Advanced Myeloma Patients: Preliminary Findings of a Multicenter, Phase II Study. (2005) (9)
- Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach (2017) (9)
- Risk of Second Primary Malignancies (SPMs) Following Bortezomib (Btz)-Based Therapy: Analysis of Four Phase 3 Randomized Controlled Trials in Previously Untreated or Relapsed Multiple Myeloma (MM) (2011) (9)
- Costs of haematological disease high and rising. (2016) (9)
- Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. (2015) (8)
- Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. (2019) (8)
- The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure. (2007) (8)
- Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2. (2021) (8)
- DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOMIB AND DEXAMETHASONE (VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): EFFICACY AND SAFETY UPDATE (CASTOR) (2017) (8)
- MyelomA Genetics International Consortium (2012) (8)
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor (2017) (8)
- Tissue distribution and myelotoxicity of daunomycin in the rat: rapid bolus injection vs continuous infusion. (1986) (8)
- Analysis of Varicella Zoster Virus Reactivation among Bortezomib-Treated Patients in the APEX Study. (2006) (8)
- Reducing Bureaucracy in Clinical Research: A Call for Action (2020) (8)
- Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network (2020) (8)
- Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications. (2006) (8)
- Health-related quality of life (HRQL) associated with bortezomib compared with high-dose dexamethasone in relapsed multiple myeloma (MM): Results from APEX study (2005) (8)
- EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies (2020) (8)
- Teniposide in lymphomas and leukemias. (1992) (8)
- A116 MP versus MPT in Elderly Myeloma Patients: The Final Outcome of the HOVON-49 Study (2009) (8)
- Cost determinants in aggressive non-Hodgkin's lymphoma. (2005) (8)
- Temporary relief of symptomatic Von Willebrand disease by multiple myeloma (2005) (8)
- Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence (2022) (8)
- Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma (2016) (8)
- Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study (2014) (7)
- Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor (2016) (7)
- Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM) (2008) (7)
- Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone and Rituximab (BDR): A Phase II Study of the European Myeloma Network (2009) (7)
- Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group. (1994) (7)
- Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab plus bortezomib/thalidomide/dexamethasone in the phase III CASSIOPEIA study (2021) (7)
- VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma (2021) (7)
- The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison (2020) (7)
- Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor (2018) (7)
- Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study (2019) (7)
- High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation (2017) (7)
- Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial. (2018) (7)
- Sequential analysis of chromosome aberrations in multiple myeloma during disease progression. (2007) (7)
- Effect of succinylated Acinetobacter glutaminase-asparaginase treatment on an acute myeloid leukemia in the rat (BNML). (1979) (7)
- Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004 (Castor). (2015) (7)
- Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis (2015) (7)
- Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2 (2021) (7)
- ACUTE LYMPHOBLASTIC LEUKAEMIA OCCURRING 6 YEARS AFTER TREATMENT OF HODGKIN'S DISEASE (1988) (7)
- Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial (2017) (7)
- Deep Vein Thrombosis in Myeloma: Estimate of Prevelance and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG). (2006) (7)
- Cytotoxicity of doxorubicin for normal hematopoietic and acute myeloid leukemia cells of the rat (2004) (7)
- Multidrug resistance (MDR) genes in haematological malignancies (1993) (7)
- Pharmacokinetics of adriamycin in the rat (1980) (7)
- MM-013: An ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI) including patients (pts) undergoing hemodialysis. (2014) (6)
- The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity. (2005) (6)
- Efficacy and Safety of Daratumumab Combined with All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma; Results of the Phase 1/2 Dara/ATRA Study (2019) (6)
- Analytical validation of SKY92 for the identification of high-risk Multiple Myeloma. (2020) (6)
- Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials (2017) (6)
- Superior Efficacy of VTD over VCD As Induction Therapy for Autotransplantation-Eligible, Newly Diagnosed, Myeloma Patients (2014) (6)
- Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma (2021) (6)
- Genetic Associations with Bortezomib Mediated Neuropathy in Multiple Myeloma. (2009) (6)
- Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study (2016) (6)
- Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach (2010) (6)
- A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (2019) (6)
- Blood and tissue distribution of cyclosporin A after a single oral dose in the rat (1984) (6)
- Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study. (2009) (6)
- The Combination of SKY92 and ISS Provides a Powerful Tool to Identify Both High Risk and Low Risk Multiple Myeloma Cases, Validation in Two Independent Cohorts (2015) (6)
- Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia (1995) (6)
- [Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. (2005) (6)
- B152 First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) (2009) (6)
- Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study (2020) (6)
- a study of 319 de novo AML patients High EVI1 expression predicts poor survival in acute myeloid leukemia (2013) (6)
- Health‐related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial (2021) (6)
- Should minimal residual disease negativity not be the end point of myeloma therapy? (2017) (6)
- Treatment of diffuse large B-cell lymphoma in the elderly: Strategies integrating oncogeriatric themes (2008) (6)
- Multidrug resistance in acute myeloid leukaemia. (1996) (6)
- Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study) (2013) (6)
- [Diagnosis and treatment of non-Hodgkin lymphoma in elderly patients]. (1997) (6)
- Future Directions in Multiple Myeloma Treatment (2005) (5)
- Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients (2021) (5)
- A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis (2018) (5)
- Pomalidomide + Bortezomib + Low-Dose Dexamethasone Vs Bortezomib + Low-Dose Dexamethasone As Second-Line Treatment in Patients with Lenalidomide-Pretreated Multiple Myeloma: A Subgroup Analysis of the Phase 3 Optimismm Trial (2018) (5)
- First report of the HOVON 45 : A phase II study with rituximab, high dose Ara-C and autologous stem cell transplantation in the primary treatment of mantle cell lymphoma. (2006) (5)
- Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia. (1987) (5)
- V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma (2021) (5)
- Transfusion of red cells after autologous bone marrow harvest in patients with acute leukemia and malignant lymphoma (1990) (5)
- 1035TiPA multicenter, randomized, phase 3 study of pomalidomide and dexamethasone (Pom-dex) with or without daratumumab in patients with relapsed or refractory multiple myeloma (RRMM): APOLLO (2017) (5)
- Trends in incidence, primary treatment and survival in chronic myelomonocytic leukaemia: a population‐based study of 1359 patients diagnosed in the Netherlands from 1989 to 2012 (2015) (5)
- Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma (2010) (5)
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial (2022) (5)
- Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF) (1992) (5)
- Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile (2021) (5)
- Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) (2014) (5)
- Perspectives on returning to work of multiple myeloma patients: A qualitative interview study (2021) (5)
- Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies. (2006) (5)
- Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study. (1990) (5)
- The relevance of cell kinetics for optimal scheduling of 1-β-d-Arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML) (2004) (5)
- Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib ± Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma. (2007) (5)
- The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B‐cell lymphomas (2011) (5)
- A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue (2014) (5)
- PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY (2019) (5)
- A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia. (2008) (5)
- Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD). (2013) (5)
- Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma (2020) (5)
- Trends in Incidence and Survival of Multiple Myeloma in the Netherlands in the Last Two Decades. Results From a National Population Based Study (2011) (5)
- Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma (2019) (5)
- [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. (2002) (5)
- Feasibility and efficacy of dose adjusted melphalan-prednisone-bortezomib (MPV) in elderly patients > 75 years of age with newly diagnosed multiple myeloma; The non-randomised phase II HOVON 123 study (2016) (4)
- Repeated daunomycin administration in rats (1984) (4)
- An update in treatment options for multiple myeloma in nontransplant eligible patients (2015) (4)
- Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study (2015) (4)
- Systematic Literature Review and Network Meta-Analysis of Treatments for Relapsed/Refractory Multiple Myeloma Patients (2016) (4)
- Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice (2020) (4)
- High-Dose Therapy in AL Amyloidosis : A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON) (2008) (4)
- A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma. (2007) (4)
- Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML (2002) (4)
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics (2021) (4)
- Immunophenotypic Analysis of Myeloma Precursors: Antigens for Therapeutic Targeting (2010) (4)
- Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma (2009) (4)
- Improving the identification of frail elderly newly diagnosed multiple myeloma patients (2021) (4)
- Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial (2021) (4)
- MDS classification is improving in an era of the WHO 2016 criteria of MDS: A population-based analysis among 9159 MDS patients diagnosed in the Netherlands. (2017) (4)
- Evidence for a possible dose-dependent pharmacokinetics of Cyclosporin-A in the rat. (1984) (4)
- Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (4)
- A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation (2012) (4)
- Pilot study of the DHAP rescue protocol and of a new conditioning regimen in responding NHL, at relapse (1989) (4)
- Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant. (2007) (4)
- P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK (2021) (4)
- A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (2019) (4)
- Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival (2015) (4)
- CN5 – Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma (2017) (4)
- Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial (2018) (4)
- FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY (2017) (4)
- Comparison Of Conventional, FISH and GEP Prognostic Factors In Multiple Myeloma: Introducing a Novel Risk Stratification (2013) (3)
- Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM) (2008) (3)
- Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials (2021) (3)
- P-gp and mrp activities in relation to treatment outcome in acute myeloid leukemia. (1999) (3)
- S1603 FIRST CLINICAL (PHASE 1B/2A) STUDY OF IBERDOMIDE (CC-220; IBER), A CELMOD, IN COMBINATION WITH DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2019) (3)
- Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma. (2007) (3)
- Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score (2021) (3)
- Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study (2017) (3)
- Impact of prior autologous stem cell transplant (ASCT) in patients receiving bortezomib or dexamethasone for relapsed/refractory multiple myeloma in the APEX trial. (2006) (3)
- Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up (2019) (3)
- Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA. (2020) (3)
- Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. (2018) (3)
- [Management in paraproteinemia]. (1992) (3)
- Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1 (2019) (3)
- Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma (2020) (3)
- Mp Versus Mpt for Previously Untreated Elderly Patientswith Multiple Myeloma: A Meta Analysis of Survival of 1682individual Patient Data From 6 Randomized Clinical Trials (2010) (3)
- P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL (2022) (3)
- Effect of Disease Stage and Time Since Diagnosis on Time to Progression for Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Relapsed or Refractory Multiple Myeloma. (2007) (3)
- Daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (CASTOR). (2017) (3)
- WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) (2016) (3)
- First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM) (2017) (3)
- Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy (2016) (3)
- Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. (2022) (3)
- Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients (2021) (3)
- Impact of prior thalidomide (T) therapy on the efficacy of pegylated liposomal doxorubicin (PLD) and bortezomib (B) in relapsed/refractory multiple myeloma (RRMM) (2007) (3)
- Role of BCRP and its expression with MDR1 in adult AML. (2005) (3)
- First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018 (2021) (3)
- The relationship of response on time to next treatment based on evidence from two RCTs in newly diagnosed stem cell transplantation ineligible multiple myeloma patients (2016) (3)
- A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. (2018) (3)
- Validation of SKY92 high and low risk prognostication in a retrospective, multinational cohort of 155 non-trial multiple myeloma patients (2019) (3)
- A phase 1b study of durvalumab (MEDI4736) alone or in combination with pomalidomide (POM) with or without low dose-dexamethasone (LoDEX) in patients (pts) with relapsed and refractory multiple myeloma (RRMM). (2016) (3)
- Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA (2019) (3)
- In vitro growth kinetics of myeloid progenitor cells of myelodysplastic patients in response to granulocyte-macrophage colony-stimulating factor and interleukin-3. (1990) (3)
- Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial (2022) (3)
- Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001 (2020) (3)
- Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: A method analysis (2004) (3)
- FINAL DONOR VERSUS NO DONOR COMPARISON OF NEWLY DIAGNOSED MYELOMA PATIENTES INCLUDED IN THE HOVON 50/54 STUDY (2010) (3)
- Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations (2020) (3)
- Car fi lzomib , cyclophosphamide , and dexamethasone in patients with newly diagnosed multiple myeloma : a multicenter , phase 2 study (2014) (3)
- Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR. (2019) (3)
- MDR 1 gene – related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia (2001) (3)
- Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study (2021) (3)
- Tumour lysis syndrome in myeloma. (2002) (3)
- Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM) (2013) (3)
- The Genetic Contribution to the Aetiology of Thalidomide Associated VTE. (2006) (3)
- PS1377 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY (2019) (3)
- A phase II study of selinexor(KPT-330) combined with bortezomib and dexamethasone (SVD) for induction and consolidation for patients with progressive or refractory multiple myeloma: The selvedex trial (2018) (3)
- Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study (2022) (2)
- Treatment of Transplant Eligible Patients with Multiple Myeloma (2018) (2)
- LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts). (2021) (2)
- Prognostic and Predictive Performance of SKY92 Combined with R-ISS in Elderly Multiple Myeloma Patients in The Hovon-87/NMSG-18 Study (2019) (2)
- Modulation of multidrug resistance in multiple myeloma. (1995) (2)
- S874 EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA (2019) (2)
- Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study (2015) (2)
- Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network (2021) (2)
- Early-Stage Economic Evaluation of Stratified Medicine in Multiple Myeloma (2013) (2)
- Developing a SNP Classifier for Predicting Peripheral Neuropathy by Bortezomib in Multiple Myeloma Patients. (2009) (2)
- Health-related quality of life in non-transplant eligible newly diagnosed multiple myeloma patients treated with melphalan/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87/NMSG18 study (2017) (2)
- Adherence to the Dutch general practitioner anemia guideline a retrospective cohort study (2013) (2)
- European Myeloma Network: The Value of Collaborative Research (2005) (2)
- Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study (2021) (2)
- The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimens. (1995) (2)
- Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform (2019) (2)
- High-resolution assessment of chromosomal gains and losses in multiple myeloma tumors from bortezomib clinical trial (2008) (2)
- PSY39 REAL-WORLD COST-EFFECTIVENESS OF BORTEZOMIB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN THE NETHERLANDS (2010) (2)
- Gastrointestinal Plasmacytomas: A Rare Finding With Important Consequences (2008) (2)
- Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison. (2020) (2)
- 8Modulation of multidrug resistance in multiple myeloma (1995) (2)
- OCEAN (OP-103): Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Older Patients (2021) (2)
- A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON) (2001) (2)
- A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE) (2019) (2)
- Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin with Bortezomib Alone in Subjects with Relapsed or Refractory Multiple Myeloma (2014) (2)
- Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group (2017) (2)
- Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma (2014) (2)
- Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity (2016) (2)
- MM-013 Phase 2, Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): Pharmacokinetics (PK) Analysis (2017) (2)
- Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM Based on Prior Lines and Treatment Exposure: CASTOR (2017) (2)
- Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished—What is Next? (2020) (2)
- Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study. (2019) (2)
- TOPSPIN: a novel algorithm to predict treatment specific survival in cancer (2017) (2)
- Efficacy and Safety of Daratumumab-Based Regimens in Patients with Relapsed/Refractory Multiple Myeloma – A Systematic Literature Review and Network Meta-analysis (2017) (2)
- The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal insufficiency (2008) (2)
- PRETREATMENT WITH THALIDOMIDE AND BORTEZOMIB DOES NOT INFLUENCE RESPONSE TO LENALIDOMIDE IN RELAPSED MYELOMA. PRELIMINARY RESULTS FROM PATIENTS INCLUDED IN DUTCH COMPASSIONATE NEED PROGRAMME (2008) (2)
- Long-Term Disease Outcomes in Symptomatic Multiple Myeloma Patients: A Retrospective Analysis of the Pharos Registry (2016) (2)
- [Multiple myeloma; treatment in the year 1998]. (1998) (2)
- Pharmacology of bromodeoxyuridine (NSC 38297) given by peripheral venous infusion (1982) (2)
- PS1374 PROGNOSIS IN ELDERLY MULTIPLE MYELOMA PATIENTS IN THE HOVON-87/NMSG-18 STUDY BASED ON REVISED ISS AND SKY92-ISS (2019) (2)
- Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study (2022) (2)
- Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT). (2014) (2)
- HOVON 104; FINAL RESULTS FROM A MULTICENTER, PROSPECTIVE PHASE II STUDY OF BORTEZOMIB BASED INDUCTION TREATMENT FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH DE NOVO AL AMYLOIDOSIS (2017) (2)
- Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]. (2021) (2)
- Real-World Evidence on Healthcare Resource use and Associated Cost With Multiple Myeloma in The Netherlands (2016) (2)
- One Line Does Not Make a Picture: Real-World Cost-Effectiveness of Multiple Myeloma Treatments Using a Full Disease Model (2013) (2)
- Antileukemic effect of high-dose thymidine in a rat model for acute myeloid leukemia (BNML). (1981) (2)
- Potential Therapeutic and Economic Value of Risk-Stratified Treatment as Initial Treatment of Multiple Myeloma in Europe (2017) (2)
- PF628 O-12-M1: AN EVALUATION OF TIME TO NEXT TREATMENT IN MELFLUFEN AND DEXAMETHASONE-TREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (2019) (2)
- Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up (2022) (2)
- Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison (2018) (2)
- PRM3 Turning the Tables to Address the Real Value of Real-World Observational Studies of Novel Anti-Cancer Agents in Multiple Myeloma (2012) (2)
- Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial (2011) (2)
- Multidrug resistance in haematological malignancies (2001) (2)
- More force or more smart? (2010) (2)
- Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment (2022) (2)
- Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis (2017) (2)
- The SKY92 prognostic marker is validated in eight multiple myeloma clinical datasets (2016) (2)
- Daunorubicin and Cytarabine Compared with Daunorubicin, Cytarabine and the MDR1 Reversal Agent PSC-833 in Elderly Patients with Acute Myelogenous Leukemia. (2004) (2)
- All IPI factors are equal, but LDH is more equal than others. (2005) (2)
- M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma (2015) (1)
- Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95) (2020) (1)
- The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma (2008) (1)
- Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial (2016) (1)
- The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow (2017) (1)
- Treatment emergent peripheral neuropathy in the CASSIOPEIA trial (2022) (1)
- S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS (2019) (1)
- P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK (2022) (1)
- OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy (2022) (1)
- Weekly Carfilzomib in combination with cyclophosphamide and dexamethasone (wCCyd) in patients (pts) with newly diagnosed Multiple Myeloma (NDMM): a phase 1/2 study of the European Myeloma Network Trialist Group (2015) (1)
- The Impact of Allogeneic Stem Cell Transplantation As Part of First Line Treatment on Outcome of Patients with Multiple Myeloma Depends on the Method of Analysis (2014) (1)
- HOVON 50/GMMG-HD3-trial (2005) (1)
- A Genome-Wide Association Study Identi fi es a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma (2016) (1)
- Multiple Myeloma--Better Drugs Ask for More Stringent Evaluations. (2015) (1)
- Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM) (2019) (1)
- Daratumumab Monotherapy in Previously Untreated High-Risk Patients with Stage 3B Light Chain (AL) Amyloidosis: A Phase II Multicenter Study By European Myeloma Network (EMN) (2019) (1)
- Multiple myeloma with amplification of chromosome 1q is highly sensitive to MCL-1 targeting (2019) (1)
- Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma (2022) (1)
- Rare Igh Translocations in Newly Diagnosed Multiple Myeloma (MM) Patients: Cytogenetic Characterization and Relevance on Prognosis (2014) (1)
- Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification (2022) (1)
- Trends in Incidence, Primary Treatment and Survival of Chronic Myelomonocytic Leukemia: A Nationwide Population-Based Study Among 1,359 Patients Diagnosed in the Netherlands from 1989 to 2012 (2014) (1)
- CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY (2016) (1)
- Innovations in treatment and response evaluation in multiple myeloma (2016) (1)
- Pharmacogenomics Study of Biological Pathways Related to Bortezomib Activity in Myeloma. (2007) (1)
- DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6) (2022) (1)
- Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (2016) (1)
- High-Risk Multiple Myeloma Patients Are Missed without Gene Expression Profiling (2020) (1)
- Report of the European Myeloma Network (EMN) workshop on multiparametric flow cytometry in multiple myeloma and related disorders (2007) (1)
- B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS (2022) (1)
- A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide- Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE) (2019) (1)
- Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials (2019) (1)
- Decreased intestinal absorption of methotrexate in the rat following repeated oral dosing. (1985) (1)
- LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy (2021) (1)
- Pharmacokinetics (PK) and pharmacodynamics (PD) of SDZ PSC 833, a novel multidrug resistance reversing agent, in phase 1 trials with chemotherapeutic agents (1997) (1)
- Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients (2010) (1)
- Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma. (2009) (1)
- Revised-international staging system (R-ISS): A new and simple prognostic assessment for multiple myeloma (2014) (1)
- Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study (2021) (1)
- Manipulation of cell cycle kinetics; influence on uptake, cellular distribution and cytotoxicity of doxorubicin☆ (1990) (1)
- Peripheral Neuropathy in the Cassiopeia Study (2020) (1)
- Content of Rat Bone Marrow Cells Quantitative Flow Cytometric Determination of Anthracycline Updated (2006) (1)
- IKZF1/3 and CRL4CRBN E3 Ubiquitin Ligase Mutations Associate with IMiD Resistance in Relapsed Multiple Myeloma (2017) (1)
- An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials (2016) (1)
- A new co-operative group: the European Myeloma Network Trialist Group (2009) (1)
- Time to relapse and age-adjusted IPI have independent prognostic valve in aggressive lymphoma enrolled in the PARMA trial at first relapse (1998) (1)
- Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years (2022) (1)
- Patterns of Primary Treatment, Trial Participation and Survival in Adult Acute Myeloid Leukemia: A Nationwide Population-Based Study Among Patients Diagnosed in the Netherlands from 1989 to 2012 (2014) (1)
- Prediction of High and Low-Risk Multiple Myeloma Based on the EMC92 Gene Expression Signature and the International Staging System (2014) (1)
- Age versus frailty: What should determine treatment choice in the elderly myeloma patients these days? (2015) (1)
- Relation Between Cereblon Expression and Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Thalidomide (2012) (1)
- Influence of genetic single nucleotide Polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and treatment related toxicity in patients with multiple myeloma treated in the HOVON 24 trial. (2005) (1)
- EHA Scientific Working Groups: Connecting Science and Spreading Knowledge in Hematology (2020) (1)
- Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes (2011) (1)
- Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands (2022) (1)
- OC-10 - Disseminated intravascular coagulation at diagnosis strongly predicts both arterial and venous thrombosis in acute myeloid leukemia patients. (2016) (1)
- Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset (2019) (1)
- Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma? (2020) (1)
- Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle (2010) (1)
- Preliminary Results From a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic Phase Myeloid Leukemia (2011) (1)
- Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR (2016) (1)
- Impact of Comorbidities on Health-related Quality of Life in Nontransplant Eligible Patients With Newly Diagnosed Multiple Myeloma (2022) (1)
- Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM's Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years (2016) (1)
- Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS (2017) (1)
- Single Cell Transcriptomic Analysis of the Multiple Myeloma Bone Marrow Identifies a Unique Inflammatory Stromal Cell Population Associated with TNF Signaling (2019) (1)
- Tissue Distribution and Myelotoxicity of Daunomycin in Normal and Leukemic Rats: Rapid Bolus Injection versus Continuous Infusion (1984) (1)
- Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients (2015) (1)
- Thalidomide: new uses for an old drug (2002) (1)
- S185: CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY (2022) (1)
- Quality of life with melphalan/prednisone plus either thalidomide (MPT-T) or lenalidomide (MPR-R) in non-transplant eligible newly diagnosed multiple myeloma: results of the HOVON87/NMSG18 study (2017) (1)
- Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma (2018) (1)
- Authors’ reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA (2022) (1)
- A robust gene expression signature to predict proteasome inhibitor benefit in Multiple Myeloma (2019) (1)
- Intensified CHOP of 12-weeks duration (I-CHOP) plus G-CSF compared with standard CHOP of 24-weeks duration (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin’s Lymphoma. A phase III trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). (2006) (1)
- Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial (2013) (1)
- Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) (1)
- Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry (2022) (1)
- Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years (2022) (1)
- MicroRNA Profiling In Multiple Myeloma (2010) (1)
- The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma (2008) (1)
- Treatment (Tx) With Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Including Those on Dialysis (2015) (1)
- Treatment Sequencing and Efficacy in Newly Diagnosed Non-Transplant Eligible Myeloma Patients in the Netherlands: A Population Based Study (2012) (1)
- PCN126 Can a Population-Based Patient Registry Improve the Feasibility of Outcomes Research in Multiple Myeloma? (2012) (1)
- Single Sample Application of the EMC92/SKY92 Signature Using the Mmprofiler (2014) (1)
- HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis (2016) (1)
- OAB-050: OCEAN (OP-103): a Phase 3, randomized, global, head-to-head comparison study of Melflufen and Dexamethasone (Dex) versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) (2021) (1)
- Short intensified therapy and autologous stem cell transplantation in adult Burkitt lymphoma. Excellent results without high-dose MTX. (2002) (1)
- Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines (2009) (1)
- Randomized phase II study LD-ARAC plus rhGM-CSF in advanced myelodysplasia (1993) (1)
- PF727 DOES QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS DIFFER BETWEEN NATIONALITIES? A EUROPEAN MULTINATIONAL STUDY (2019) (1)
- Polymorphisms in the Multiple Drug Resistance Protein 1 and in P-Glycoprotein 1 Are Associated with Time to Event Outcomes in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Bortezomib and Pegylated Liposomal Doxorubicin. (2009) (1)
- Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial - Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal (2018) (0)
- PF595 POMALIDOMIDE + BORTEZOMIB + LOW-DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE-PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL (2019) (0)
- HemaSphere: A New Rising Star in the Field of Hematology Journals (2018) (0)
- The Peripheral Cannabinoid Receptor CB2 and CD40 Are Novel Biological Markers That Predict Outcome in Diffuse Large B-Cell Lymphoma of Elderly Patients. (2004) (0)
- Impact of Baseline Free Light Chain Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal Doxorubicin Plus Bortezomib or Bortezomib Alone. (2009) (0)
- Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (2016) (0)
- Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study (2020) (0)
- Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma (2022) (0)
- Molecular Subtyping and Risk Stratification for the Classification of Myeloma (2015) (0)
- Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison (2019) (0)
- P-072: Progression and dissemination of experimental multiple myeloma is associated with loss of innate and adaptive immune-mediated tumor control (2021) (0)
- RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response (2015) (0)
- High-Dose Therapy in AL Amyloidosis (2008) (0)
- Health-Related Quality of Life in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients Treated with Either Thalidomide or Lenalidomide-Based Regimen Until Progression (HOVON-87/NMSG18 Study): A Prospective, Open-Label, Multicenter, Randomized, Phase 3 Study (2019) (0)
- monoclonal antibody in relapsed or refractory follicular lymphoma: First clinical use of ofatumumab, a novel fully human anti-CD20 (2013) (0)
- CLINICAL TRIALS OBSERVATIONS BDR in newly diagnosed patients with WM: fi nal analysis of a phase 2 study after a minimum follow-up of 6 years (2017) (0)
- Escalated Dose Bortezomib Once Weekly Combined with Lenalidomide and Dexamethasone (eVRD) Followed by Lenalidomide Maintenance in First Relapse of Multiple Myeloma (MM). the HOVON 86 Phase 2 Trial (2012) (0)
- MCL-1 Inhibition Is Highly Effective Against Multiple Myeloma Cells from Poor Prognosis Patients (2018) (0)
- Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology (2018) (0)
- in CD34+ acute myeloid leukemia cells Predominance of functional multidrug resistance (MDR-1) phenotype (2011) (0)
- Mouse monoclonal antibodies directed against a recombinant peptide homologous to human MDR3 membrane P-glycoprotein.: 28 (1994) (0)
- Eight versus four induction cycles of Carfilzomib, Thalidomide and Low-dose Dexamethasone: the Carthadex trial (2019) (0)
- Multiple myeloma: Management of De novo disease to include HDT (2011) (0)
- Effect of estradiol (E2) on cell cycle distribution of MCF-7 Human breast cancer cells: Analysis by flow cytometry (PI) and immunocytochemistry (Ki-67) (1987) (0)
- Geriatric assessment predicts survival and risk of serious adverse events for elderly newly diagnosed multiple myeloma patients. (2014) (0)
- Bortezomib during induction and maintenance before and after autologous transplantation improves overall survival in patients with renal impairment: subgroup analysis from the HOVON-65/GMMG-HD4 randomized trial for newly diagnosed multiple myeloma (2011) (0)
- PS1516 COST-EFFECTIVENESS OF RISK-STRATIFIED TREATMENT IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA (2019) (0)
- A High-Risk Survival Classifier for Multiple Myeloma (2011) (0)
- A285 The Dutch Lenalidomide Named Patient Program: Results and Feasibility in Heavily Pretreated Patients (2009) (0)
- Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results (1992) (0)
- OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis (2021) (0)
- Expression of m & l and m & 3 Multidrug-Resistance Genes in Hairy Cell Leukaemia (2003) (0)
- NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma (2023) (0)
- A new multiple myeloma classification system that correlates to disease stage and prognosis: Indication of reversible phenotypic plasticity as a hallmark (2016) (0)
- MicroRNAs Are Differentially Expressed Among Cytogenetic Subgroups in Multiple Myeloma. (2009) (0)
- Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Mye (2021) (0)
- Immune-mediated tumor control in the 5TGM1 transfer model of multiple myeloma (2023) (0)
- Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. (2022) (0)
- Running Title: Genetic factors underlying the risk of BiPN in multiple myeloma patients (2011) (0)
- The Sense and Nonsense of Anaemia Analysis in Relation to Mortality in General Practice (2015) (0)
- P-062: MAF translocations are enriched in high-risk NDMM patients with elevated levels of circulating tumor cells suggesting a genetic basis for the aggressive disease course (2022) (0)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients (2020) (0)
- Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response. (2005) (0)
- MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMA (2018) (0)
- Phase III Trials for Multiple Myeloma in Northern Europe (2009) (0)
- Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible (2020) (0)
- Kinetics of daunomycin in leukemia cells and leukocytes in vivo in the rat. (1987) (0)
- High Levels of Circulating Tumor Cells Are Associated with Increased Bone Marrow Proliferation in Newly Diagnosed Multiple Myeloma Patients (2021) (0)
- CHOP C ompared W ith C HOP P lus G ranulocyte C olony- Stimulating F actor i n E lderly P atients W ith A ggressive Non-Hodgkin's L ymphoma (2003) (0)
- No Evidence of MDR1 Gene Related Clonal Selection in Relapsed or Refractory Acute Myeloid Leukemia (AML) (2003) (0)
- Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects (2022) (0)
- PF596 EFFICACY AND SAFETY OF DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE (D-VD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF CASTOR BASED ON CYTOGENETIC RISK (2019) (0)
- B551 A Novel Chemosensitivity Index for Chemotherapy Correlates to Resistance and Refractoriness (2009) (0)
- and activity leukemia: correlation between assays for P-glycoprotein expression Quality control of multidrug resistance assays in adult acute (2011) (0)
- Safety and Efficacy of Ciltacabtagene Autoleucel (cilta-cel), a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: Results from Cartitude-2 (2022) (0)
- Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis (2020) (0)
- All formulations of hydroxyethyl starch are not the same - Reply (2007) (0)
- P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY (2022) (0)
- DEVELOPMENT OF PERIPHERAL NEUROPATHY IN MULTIPLE MYELOMA PATIENTS; INCIDENCE, MOLECULAR CHARACTERIZATION AND EFFECT ON RESPONSE IN BORTEZOMIB VS CONVENTIONAL TREATMENT (2010) (0)
- VA.2 Clinical trials in non-Hodgkin's lymphoma in elderly patients (2006) (0)
- Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma. (2014) (0)
- Melflufen in multiple myeloma: the conclusion matters - Authors' reply. (2022) (0)
- Bortezomib-induced peripheral neuropathy: facts and genes – Authors' reply (2011) (0)
- Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). (2023) (0)
- Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials (2019) (0)
- Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (2020) (0)
- Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial (2020) (0)
- Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching (2020) (0)
- PF559 IBERDOMIDE (CC-220) IS PHARMACODYNAMICALLY ACTIVE AND HAS DOSE-DEPENDENT IMMUNOSTIMULATORY ACTIVITY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IRRESPECTIVE OF PRIOR IMID DRUG TREATMENT (2019) (0)
- GENETIC VARIATIONS ASSOCIATED WITH TREATMENT RESPONSE, PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA IN THE HOVON 50/GMMG-HD3 TRIALS (2010) (0)
- Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM). (2019) (0)
- MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course (2022) (0)
- Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study (2023) (0)
- P-glycoprotein and CD34 double expression and altered Ara-C metabolism are associated with autonomous proliferation in adult acute myeloid leukemia: 111 (1994) (0)
- Reply (2007) (0)
- Multiple Myeloma Subtyping That Associates Normal B-Cell Subset Phenotypes, do Correlate to Disease Stage and Prognosis: Indication of Reversible Phenotypic Plasticity as a Hallmark (2015) (0)
- An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich microenvironment in multiple myeloma (2023) (0)
- Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial (2017) (0)
- Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (0)
- Immunophenotypic Analysis of Myeloma Precursors (2010) (0)
- The Role of Mutations in the Deoxycytidine Kinase (dCK) Gene in the Development of Acute Myeloid Leukemia (AML) Towards Relapsed and/or Refractory Disease (2003) (0)
- Addition of cyclosporin A (CSA) to Mitoxantrone and Etoposide (MVP) to overcome chemotherapy resistance in relapse and refractory AML (2001) (0)
- Phase 2 study of car fi lzomib , thalidomide , and dexamethasone as induction / consolidation therapy for newly diagnosed multiple myeloma (2014) (0)
- 4TH INTERNATIONAL SYMPOSIUM ON LEUKEMIA AND LYMPHOMA-MOLECULAR PHARMACOLOGY AND NEW TREATMENT MODALITIES (2000) (0)
- OAB-043: Ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma and early relapse after initial therapy: biological correlative analyses and updated clinical results from CARTITUDE-2 Cohort B (2022) (0)
- Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker (2019) (0)
- Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects (2018) (0)
- Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome (2022) (0)
- Malignant LymphomasDecision Making and Problem Solving (2005) (0)
- Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients (2022) (0)
- of 1175 patients overall survival in elderly myeloma treated with novel agents: analysis Complete response correlates with long-term progression-free and (2012) (0)
- report of the International Myeloma Workshop Consensus Panel 2 Consensus recommendations for risk stratification in multiple myeloma (2011) (0)
- Prognostic value of positron emission tomography/computed tomography in transplant-eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study (2022) (0)
- Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis (2016) (0)
- Inflammasome-Primed Myeloid Cells Maintain a Pro-Tumor Microenvironment in Multiple Myeloma (2021) (0)
- Rare High Risk IgH Translocations in Newly Diagnosed Multiple Myeloma (MM): Cytogenetic Characterization and Relevance on Prognosis (2015) (0)
- The Dutch Lenalidomide Named Patient Program (2009) (0)
- 998 A phase II study of a novel taxane BAY 59-8862 in patients with aggressive refractory non-Hodgkin's lymphoma (2003) (0)
- Depending on Receptor Activation Status Cannabinoid Receptor in Lymphoid Tissues Distinct Expression Profiles of the Peripheral (2004) (0)
- Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic (2021) (0)
- Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma : Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib (2010) (0)
- PF556 PRECLINICAL EVALUATION OF THE NEW GPRC5DXCD3 (JNJ-7564) BISPECIFIC ANTIBODY FOR THE TREATMENT OF MULTIPLE MYELOMA (2019) (0)
- Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma (2021) (0)
- Vaults and drug resistance: What we learn from an MVP/LRP knockout mouse model. (2004) (0)
- OAB-014: Newly diagnosed Multiple Myeloma patients with high levels of circulating tumor cells are distinguished by increased bone marrow plasma cell proliferation (2021) (0)
- Multiple myeloma subtyping that associatesnormal B-cell subset phenotypes, do correlate to disease stage and prognosis (2015) (0)
- Abstract 4737: Genetic determinants associated with multiple myeloma risk in three large population sets (2010) (0)
- Validation of the EMC92/SKY92 Signature in HOVON-87/Nmsg-18: Gene Expression Based Prognostication Is Applicable in Elderly Patients with Newly Diagnosed Multiple Myeloma (2015) (0)
- P-082: Stromal cell - neutrophil interactions are driving a pro tumor environment in multiple myeloma (2022) (0)
- [Diagnosis and treatment of malignant histiocytosis]. (1989) (0)
- In Vivo Pharmacokinetics of Daunorubicin in Bone Marrow in Adult Acute Nonlymphocytic Leukaemia (1984) (0)
- Thalidomide/dexamethasone in myeloma: a double-edged sword. (2009) (0)
- Single-Cell Transcriptomic Analysis Reveals Loss of Activated Bone Marrow NK Cells in Multiple Myeloma Patients Which Associates with Disease Progression in Mice (2021) (0)
- Gene Expression Profiles for Molecular Classification of Multiple Myeloma in Newly Diagnosed Patients Included in a Prospective, Multicenter, Phase 3 Trial. (2008) (0)
- Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma (2022) (0)
- autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the (2012) (0)
- OCEAN (OP-103): Melflufen/Dexamethasone Compared Wth Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - Subgroup Analysis in Patients Refractory to Prior Alkylators (2022) (0)
- prospective sibling donor versus no-donor comparison adult patients with acute lymphoblastic leukemia in first remission: a Myeloablative allogeneic versus autologous stem cell transplantation in (2013) (0)
- Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia, (2011) (0)
- Prolonging time to progression and survival in relapsed/refractory multiple myeloma (2009) (0)
- Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome (2022) (0)
- Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network (2019) (0)
- Targeted Genomic Mutation Panel (M3 P) Results from 504 Multiple Myeloma (MM) Patients (2015) (0)
- Measuring hospital-related burden of treatment in multiple myeloma using Electronic Health Records’-reimbursement data (2022) (0)
- expression in relapsed or refractory acute myeloid leukemia related clonal selection and P-glycoprotein function and - MDR1 gene (2013) (0)
- B562 Increasing Numbers of Most Mature Peripheral Blood B-Subsets are Observed in Monoclonal Gammopathies (2009) (0)
- Clinical pharmacological meeting (1984) (0)
- A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials (2017) (0)
- Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial (2010) (0)
- Treatment of t(4;14) and del(17p) in multiple myeloma (2018) (0)
- Effect of whole-body irradiation on skeletal growth in rhesus monkeys. [X rays] (1979) (0)
- The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy (2014) (0)
- Pharmacokinetics of oral methotrexate in bone marrow during maintenance treatment of childhood acute lymphocytic leukemia. (1987) (0)
- POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS (2020) (0)
- OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status (2021) (0)
- Immune Profiling of Multiple Myeloma Patients Treated with Daratumumab Monotherapy: Acquired and Primary Daratumumab-Resistance Is Associated with NK Cell Exhaustion (2021) (0)
- OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses (2021) (0)
- Minimal Residual Disease (MRD) follow up of MM patients obtaining stringent complete remission (sCR) in the NMSG/EMN02 clinical trial – defining sCR numbers and prediction of disease progression by multiparametric flow cytometry (MFC). (2018) (0)
- P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13 (2022) (0)
- bortezomib- containing regimens cell collection following initial therapy with thalidomide, lenalidomide or Mobilization in myeloma revisited: IMWG consensus perspectives on stem (2009) (0)
- [A patient with a severe injury of the back of the hand following extravasation of doxorubicin]. (1984) (0)
- Hormonal manipulation of MCF-7 breast cancer cells: Implications for chemotherapy (1986) (0)
- A patient with a glioblastoma multiforme mimicking a brain abscess by producing high levels of granulocyte-colony stimulating factor (1998) (0)
- Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study (2019) (0)
- deletion 17p transplantation improves outcome in multiple myeloma patients with Administration of bortezomib before and after autologous stem cell (2012) (0)
- P-260: Daratumumab (DARA) plus bortezomib and dexamethasone (D-Vd) or lenalidomide and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): subgroup analyses of CASTOR and POLLUX (2022) (0)
- Time to Next Treatment Is Response Dependent and Treatment Independent Based on Evidence from RCTs in Stem Cell Transplantation Eligible Multiple Myeloma Patients (2014) (0)
- The EHA2021 Annual Congress Award Winners: Celebrating Excellence in Hematology (2021) (0)
- An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma (2014) (0)
- B01: STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT IN MULTIPLE MYELOMA (2022) (0)
- Advanced age, organ damage and adverse events negatively affect survival of myeloma patients receiving novel agents: A meta-analysis of 1435 individual patient data from 4 randomized clinical trials (2012) (0)
- Phase I/II trial of Lenalidomide plus Bortezomib combined with Dexamethasone in patients in 1st relapse or primary refractory after first line therapy for Multiple Myeloma (2010) (0)
- The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018 (2023) (0)
- PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D-RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK (2019) (0)
- PB2117 POMALIDOMIDE PLUS LOW-DEXAMETHASONE TREATMENT FOR ≥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MM-013 PHASE 2 STUDY (2019) (0)
- Identification and Validation of IMiD-14 Model Predictive of IMiD Resistance in Multiple Myeloma (2015) (0)
- Pomalidomide + Bortezomib + Low-Dose Dexamethasone after 1 Prior Line of Therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem Cell Transplant (2019) (0)
- Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells (2018) (0)
- Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse (2018) (0)
- 998PDManagement of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX (2017) (0)
- Somatic Mutations and Polymorphisms of the Glucocorticoid Receptor Gene Are Not Related to Glucocorticoid Resistance in Childhood ALL. (2004) (0)
- Malignant transformation of hematopoietic stem cells: pathophysiology and development of therapy (1988) (0)
- PCN127 Policy Maker, Please Carefully Consider Your Needs: Does Outcomes Research of Bortezomib for Advanced Multiple Myeloma Reduce Uncertainty? (2012) (0)
- Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016) (2016) (0)
- A046 HOVON-50 Final Analysis of Thalidomide Combined with Adriamycin, Dexamethasone, and HDM (2009) (0)
- Multiple myeloma gammopathies A high-risk , Double-Hit , group of newly diagnosed myeloma identi fi ed by genomic analysis (2018) (0)
- Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance (2021) (0)
- Virtual Karyotype Reconstruction By SNPs Array of Newly Diagnosed Multiple Myeloma (MM) Patients Enrolled in the EMN02 Clinical Trial (2014) (0)
- The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS (2020) (0)
- Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS (2019) (0)
- Expression of Cancer Testis Antigens as Potential Targets for Immunotherapy Is Retained Following Treatment in Multiple Myeloma. (2008) (0)
- Intensification therapy with autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A multicenter, phase III study of the european myeloma network (EMN02/HO95 MM trial) (2017) (0)
- Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial (2022) (0)
- Pomalidomide + Bortezomib + Dexamethasone After One Prior Line of Therapy in Bortezomib-Pretreated Multiple Myeloma: Subanalysis of OPTIMISMM (2019) (0)
- Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years. (2005) (0)
- CHALLENGES IN THE MANAGEMENT OF HIGH-RISK MULTIPLE MYELOMA (2023) (0)
- A Multicenter Phase I/II EMN Study of Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma (2017) (0)
- Patternator for complete sprayer research (1976) (0)
- Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes (2019) (0)
- Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma (2020) (0)
- Reply to C.A. Dasanu et al (2009) (0)
- Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial (2022) (0)
- Gene Expression Profiles as Prognostic Factors in Patients with Multiple Myeloma Treated with Conventional Versus Novel Agents in Correlation with Outcome. (2007) (0)
- B340 Molecular Classification of Newly Diagnosed MM Patients Included in a Prospective Phase III Trial (2009) (0)
- P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY (2022) (0)
- [On the road to cure of multiple myeloma?]. (1992) (0)
- Melphalan Resistance in Multiple Myeloma Can Be Overcome by Proteasome Inhibition or Histone Deacetylation: Lack of Syngergism of the Combination. (2005) (0)
- A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus (2014) (0)
- patients from the International Myeloma Working Group favorable features and shows better survival: an analysis of 10 549 Myeloma in patients younger than age 50 years presents with more (2008) (0)
- Subject Index Vol. 70, 2006 (2007) (0)
- No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study (2013) (0)
- Minimal Residual Disease by Flow Cytometry and ASO-RQ-PCR in Myeloma Patients Receiving Lenalidomide Maintenance: A Pooled Analysis MRD and ASO-RQ-PCR in MM patients (2019) (0)
- In reply [4] (2005) (0)
- Identification of mutations in WFS 1 in Dutch patients with Wolfram syndrome (2002) (0)
- Reply to X. Armoiry et al. (2017) (0)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients Running title : GWAS in multiple myeloma pharmacogenomics (2016) (0)
- The Risk Classification based on Gene Expression Profiling: a Tool for Prediction of High- and Low-risk Multiple Myeloma across International Trials (2015) (0)
- Impact of complete response on progression-free survival and overall survival in newly diagnosed myeloma patients treated with autologous stem cell transplantation or conventional chemotherapy: results of a pooled analysis of 5 phase III trials (2015) (0)
- Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features (2016) (0)
- OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis (2021) (0)
- Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19) (2022) (0)
- P-080: Single-cell transcriptomic analysis of bone marrow NK cells reveals loss of activated cytotoxic NK cells in Multiple Myeloma (2021) (0)
- Diagnosis of Anaemia in Patients Presenting to the General Practitioner: Causes and Survival (2014) (0)
- P-069: Inflammasome-primed neutrophils maintain a pro-tumor microenvironment in Multiple Myeloma (2021) (0)
- Concentrations of ciclosporin in allogeneic bone marrow recipients (1987) (0)
- High-Resolution Assessment of Gains and Losses of Chromosomes in Patients with Multiple Myeloma Treated with Bortezomib. (2007) (0)
- Multiple myeloma diagnostics: the role of imaging, chromosome analysis and multiparameter flowcytometry (2011) (0)
- MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma (2022) (0)
- PS1385 THE IMPACT OF A PRIOR MALIGNANCY ON THE DEVELOPMENT OF A SUBSEQUENT MALIGNANCY IN MULTIPLE MYELOMA REVISITED: A COMPETING RISK ANALYSES (2019) (0)
- Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma (2019) (0)
- MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy. (2022) (0)
- PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS (2019) (0)
- Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma (2022) (0)
- Gene expression profiles as prognostic factors for high-dose therapy and bortezomib in patients with multiple myeloma (2007) (0)
- Contents Vol. 70, 2006 (2007) (0)
- 1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma (2018) (0)
- PRM177 What is the Role of Early Health Technology Assessment of Biomarkers in the Pre-Clinical Development Phase? A Reflection on Lessons Learned With Multiple Myeloma (2012) (0)
- No evidence of selection of a MDR1 gene related drug resistant clone in relapsed/refractory AML (2000) (0)
- P-021: 7C6 is a novel monoclonal antibody that induces enhanced anti-myeloma activity of cytokine induced memory-like (CIML) NK cells by blocking MICA/B shedding and antibodydependent cell cytotoxicity (2022) (0)
- Abstract 5023: Multiple myeloma with a clonal del17p aberration is characterized by somatic TP53 mutations, which negatively affect prognosis in this cytogenetic subgroup (2016) (0)
- [Multidrug resistance in hematological malignancies: prognostic significance and the effect of resistance-modulating drugs]. (1994) (0)
- Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Pieter Sonneveld?
Pieter Sonneveld is affiliated with the following schools:
